Cancer kills 1 in 6 people, yet 95% of drugs fail because legacy artificial models lack human relevance. Calico Biosystems is the only platform testing drugs directly on native patient tumors to reliably predict clinical outcomes. By merging experimental human data with digital modeling (NAMs), we identify potent synergies and slash R&D timelines by 24 months.

We provide drug developers with a Biological Truth Layer to future-proof pipelines against the FDA Modernization Act 2.0. Poised to capture 8% of a $250B market by 2030, Calico replaces high-attrition animal testing with human-centric certainty, transforming the value chain from pharmacology to the clinic.
Together, we accelerate the delivery of life changing treatments to patients with unprecedented speed and precision.

News

Milestones/News

01.05.2026 Comment on the FDA’s groundbreaking March 2026 Draft Guidance for New Approach Methodologies (NAMs) regarding Patient-native systems
01.04.2026 Strategic collaborations initiated with industry leaders, including a global US-based CRO
01.01.2026 Platform validated on 300+ patient tumors across multiple oncology indications.
01.01.2026 CBO hired
01.09.2025 First commercial customers secured across biotech and pharmaceutical sectors

Videos and Presentations


Our technology